Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis

This is a resubmission, previous reviewers' reports and the authors' replies have been shown here. 

Previous Reviewer 1 Report:

It is not clear presented the methods used for calculation the additive/antagonic effect.

Addtional mechanistic evaluation need to be done to sustain the conclusions"According to isobolographic analysis, we have determined that CAM and PAX produce antagonistic interaction in TNBC cells lines, which could inhibit their anti-cancer efficacy in BC treatment, showing the importance of preclinical testing."

The conclusion need to be more specific, in agreement with the main findings of the study.

Authors' previous reply:

Please see the attachment. 

-----------------------------

Previous Reviewer 2 Report:

The manuscript explains the combinational use of two drugs CAM and PAX and their importance in preclinical testing in triple-negative breast cancer cells. The findings of the manuscript are interesting and it is well written. However, a few points are needed to address before acceptance for publication.

1. The authors have mainly focussed on triple-negative breast cancer cells. Although it would be interesting to see the results in Estrogen receptor-positive breast cancer cells.
2. I would recommend authors confirm the drug’s efficacy of Cambinol in the presence or absence of PAX.
3. To better support, CAM and PAX individually induced apoptosis or combination antagonistic effects, authors should include Annexin V and/or Western blot of key apoptotic markers.

Authors' previous reply:

Please see the attachment. 

Then the authors resubmit this manuscript with a new ID, previous reviewers provided their reports on the revised version.

Round 1

Reviewer 1 Report

-

Reviewer 2 Report

Accept in current form